GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyoutnews2026-07-17T11:05:17+00:00July 17th, 2026|Endpoints News|
Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hirenews2026-07-17T11:00:13+00:00July 17th, 2026|Endpoints News|
Mirador unveils part of pipeline with drug from Kira to rival Tavneosnews2026-07-16T21:47:22+00:00July 16th, 2026|Endpoints News|
What health system execs are talking aboutnews2026-07-16T16:10:38+00:00July 16th, 2026|Endpoints News|
Kelun pads efficacy profile of Merck-partnered ADC; Europe will have to wait for Boehringer’s Hernexeosnews2026-07-16T15:18:38+00:00July 16th, 2026|Endpoints News|
Q&A: Betty Tijms wants to stop treating Alzheimer’s as a single diseasenews2026-07-16T14:53:37+00:00July 16th, 2026|Endpoints News|
US drug shortages rise for third straight quarter, hurt by lone suppliersnews2026-07-16T14:13:57+00:00July 16th, 2026|Endpoints News|
Updated: Sanofi, Arbutus file separate suits against mRNA vaccine makers over LNP tech patentsnews2026-07-16T11:35:38+00:00July 16th, 2026|Endpoints News|
Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckleynews2026-07-16T11:09:28+00:00July 16th, 2026|Endpoints News|
Merck beats AstraZeneca to first approval for first PCSK9 pillnews2026-07-16T10:45:08+00:00July 16th, 2026|Endpoints News|
